Non-standard MA’s are less frequent in the non-orphan medicines group but, as in the orphan medicines group, we observe an increasing trend of this type of MA’s over the period studied (Fig. 3 ).
← all excerpts
Trends in orphan medicinal products approvals in the European Union between 2010-2022.
1
—
—